Shenzhen Edge Medical priced an initial public offering on the Hong Kong Exchange to raise HKD1.19 billion (about US$154 million) to fund R&D, scale manufacturing and expand internationally. The offering signals robust investor interest in surgical robotics after a banner year for med‑tech IPOs. Edge will list on Jan. 8, 2026, and plans to deploy proceeds toward next‑generation robotic platforms and global sales channels. The IPO reflects broader market receptivity to med‑tech companies that can demonstrate near‑term commercialization paths for robotic surgery systems.